| P50 | author | Massimo Dominici | Q56849926 |
| | Giulia Grisendi | Q57012601 |
| | Filippo Rossignoli | Q85892125 |
| | Giulia Orsi | Q87771986 |
| | Giulia Golinelli | Q87920946 |
| | Giulia Rovesti | Q89326396 |
| P2093 | author name string | Alessandra Recchia | |
| | Edwin M Horwitz | |
| | Elena Veronesi | |
| | Carlotta Spano | |
| P2860 | cites work | Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers | Q74370488 |
| | Mesenchymal stem/stromal cells as a delivery platform in cell and gene therapies | Q26799107 |
| | Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement | Q27861120 |
| | Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells | Q28391040 |
| | Inducible apoptosis as a safety switch for adoptive cell therapy | Q29617710 |
| | Molecular mechanism for ganciclovir resistance in human T lymphocytes transduced with retroviral vectors carrying the herpes simplex virus thymidine kinase gene. | Q31774891 |
| | Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial | Q35372367 |
| | Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation | Q35849500 |
| | Frontiers in Suicide Gene Therapy of Cancer | Q36534930 |
| | Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy | Q37140126 |
| | Suicide Gene Therapy for Cancer - Current Strategies | Q37347017 |
| | How do mesenchymal stromal cells exert their therapeutic benefit? | Q37352910 |
| | Human bone marrow and adipose tissue mesenchymal stem cells: a user's guide | Q37756932 |
| | Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers | Q37948053 |
| | Mesenchymal Stem Cell Therapy for Autoimmune Disease: Risks and Rewards | Q38525790 |
| | TRAIL delivered by mesenchymal stromal/stem cells counteracts tumor development in orthotopic Ewing sarcoma models | Q38750240 |
| | Combination of immortalization and inducible death strategies to generate a human mesenchymal stromal cell line with controlled survival | Q39021594 |
| | Treatment of Acute Myeloid Leukemia with T Cells Expressing Chimeric Antigen Receptors Directed to C-type Lectin-like Molecule 1. | Q40135347 |
| | An inducible caspase 9 safety switch for T-cell therapy | Q41768001 |
| | Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation | Q41953436 |
| | An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapies | Q42622440 |
| | Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial | Q43063875 |
| | Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy | Q43100976 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1-2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 11-16 | |
| P577 | publication date | 2018-06-29 | |
| P1433 | published in | Cancer Gene Therapy | Q15763088 |
| P1476 | title | Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy | |
| P478 | volume | 26 | |